Business
Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
CHICAGO, December 03, 2025--Cardio Diagnostics announced that CMS has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests.
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1086,"height":272,"url":"https://media.zenfs.com/en/business-wire.com/21bc064795acba7d6aa4bd1d69a7c26f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oO309CrTHZ7Zv9If7UIC9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/21bc064795acba7d6aa4bd1d69a7c26f","width":960,"height":240},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/UN7nE6_kbztp9lQAhFPyAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxNzI7aD01NDQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/21bc064795acba7d6aa4bd1d69a7c26f","width":1086,"height":272}},"lazy":false},{"type":"text","content":"The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™.","length":204,"tagName":"p"},{"type":"text","content":"CHICAGO, December 03, 2025--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Obtaining the final rate represents a positive development and will be effective for claims with dates of service on or after January 1, 2026.","length":609,"tagName":"p"},{"type":"text","content":""We are pleased with the final payment rate," said Meesha Dogan, PhD., CEO and Co-Founder of Cardio Diagnostics. "Obtaining the final rate is a significant step in our efforts to expand access to our advanced cardiovascular tests for Medicare beneficiaries."","length":278,"tagName":"p"},{"type":"text","content":"Cardiovascular disease remains the leading cause of death in the United States, particularly among Americans aged 65 and older. In 2022 alone, over 700,000 Americans died from heart disease, with coronary heart disease (CHD) accounting for more than 370,000 deaths.","length":265,"tagName":"p"},{"type":"text","content":"PrecisionCHD™ is a groundbreaking AI-powered t...